XML 20 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 33,509 $ 25,175
Accounts and note receivables, net 15,552 17,136
Inventories, net 4,281 6,122
Prepaid assets 1,547 377
Other current assets 1,045 843
Total current assets: 57,221 49,653
Property and equipment, net 23,288 17,709
Intangible assets, net 205 297
Right-of-use assets 489 666
Land use rights, net 1,493 1,559
Deferred tax assets 4,695 4,081
Long-term certificates of deposit 23,431 7,394
Other assets, noncurrent 995 3,394
Total assets 116,539 84,753
Current liabilities:    
Accounts payable 355 122
Deferred revenue 39 145
Due to related parties 1,369 118
CVR excess closing cash payable 1,085  
Accrued expenses and other current liabilities 11,935 9,264
Income tax payable 5,054 2,101
Operating lease liabilities, current 210 492
Total current liabilities: 20,047 12,242
Operating lease liabilities, noncurrent 199 121
Deferred government grants 213 118
CVR derivative liability, noncurrent 4,722  
Warrant liability, noncurrent 12,835  
Other noncurrent liabilities 49 55
Total liabilities 38,065 12,536
Commitments and Contingencies (Note 13)
Equity:    
Common stock, $0.001 par value, 400,000,000 shares authorized; 76,595,616 shares and 63,588,119 shares issued and outstanding at December 31, 2023 and 2022, respectively 77 64
Additional paid-in capital 68,179 32,795
Statutory reserve 3,098 2,660
(Accumulated deficit) retained earnings (85,538) 7,395
Accumulated other comprehensive loss (1,644) (392)
Total Gyre stockholders' (deficit) equity (15,828) 42,522
Noncontrolling interest 29,777 29,695
Total equity 13,949 72,217
Total liabilities, convertible preferred stock, and equity 116,539 $ 84,753
GC Biopharma Corp    
Current assets:    
Long-term receivable from GCBP 4,722  
GNI    
Current assets:    
Other receivables from GNI 1,287  
Convertible Preferred Stock    
Current liabilities:    
Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; 13,151 shares and nil shares issued and outstanding at December 31, 2023 and 2022, respectively $ 64,525